Albert Bourla, CEO of Pfizer, expressed that the company might shift its drug manufacturing back to the U.S. if President Trump's anticipated tariffs impact operations overseas. Speaking at the TD Cowen healthcare conference, Bourla emphasized the strength of Pfizer's U.S. manufacturing network, which includes 13 operational sites. He acknowledged the risks and opportunities stemming from the new administration, reinforcing Pfizer's strategy to align closely with governmental policies and adapt as necessary to changes in the trade environment.
Albert Bourla's remarks at the TD Cowen healthcare conference highlighted Pfizer's intent to adapt to potential tariffs by possibly relocating drug manufacturing back to the U.S.
Pfizer currently operates 13 manufacturing sites in the U.S., showcasing a solid domestic presence amid discussions about moving production due to external tariffs.
Collection
[
|
...
]